Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: A cross-sectional, observational study

Clinical and Experimental Rheumatology

Volumn 34, Issue 1, 2016, Pages 148-154

  Pieter Van Dijkhuizen, E H ^a,b   Pouw, Juliëtte N ^a   Scheuern, Andrea ^c   Hügle, Boris ^c   Hardt, Sven ^d   Ganser, Gerd ^d   Kümmerle Deschner, Jasmin Beate ^e   Horneff, Gerd ^f   Holzinger, Dirk ^g   Calasan, Maja Bulatovic ^a   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b G GASLINI INSTITUTE   (Italy)

^c German Centre for Pediatric and Adolescent Rheumatology   (Germany)

^d St Josef Stift   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f Asklepios Klinik Sankt Augustin   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adverse effects; Juvenile idiopathic arthritis; Methotrexate; Route of administration; Subcutaneous injections

Indexed keywords

METHOTREXATE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BEHAVIOR DISORDER; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSAGE SCHEDULE COMPARISON; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GERMANY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; METHOTREXATE INTOLERANCE SEVERITY SCORE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RESTLESSNESS; SCHOOL CHILD; TREATMENT DURATION; VOMITING; ADOLESCENT BEHAVIOR; AGE; ARTHRITIS, JUVENILE; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CHILD BEHAVIOR; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; MULTIVARIATE ANALYSIS; ODDS RATIO; ORAL DRUG ADMINISTRATION; RISK FACTOR; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADOLESCENT; ADOLESCENT BEHAVIOR; AGE FACTORS; ARTHRITIS, JUVENILE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD BEHAVIOR; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; LOGISTIC MODELS; MALE; METHOTREXATE; MULTIVARIATE ANALYSIS; NAUSEA; ODDS RATIO; PREVALENCE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; VOMITING;

EID: 84958768003     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. PRAKKEN B, ALBANI S, MARTINI A: Juvenile idiopathic arthritis. Lancet 2011; 377: 2138-49.
2. RUPERTO N, MURRAY KJ, GERLONI V et al.: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50:2191-201.
3. HASHKES PJ, LAXER RM: Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294: 1671-84.
4. FOELL D, WULFFRAAT N, WEDDERBURN LR et al.: Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303: 1266-73.
5. PRINCE FH, van SUIJLEKOM-SMIT LW:Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked. Paediatr Drugs 2013; 15: 271-80.
6. CHICKERMANE PR, KHUBCHANDANI RP: Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate. Clin Exp Rheumatol 2015; 33: 287-92.
7. NIEHUES T, LANKISCH P: Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr Drugs 2006; 8: 347-56.
8. ALSUFYANI K, ORTIZ-ALVAREZ O, CABRAL DA, TUCKER LB, PETTY RE, MALLESON PN: The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31: 179-82.
9. HASHKES PJ, BECKER ML, CABRAL DA et al.: Methotrexate: new uses for an old drug. J Pediatr 2014; 164: 231-6.
10. MURRAY KJ, LOVELL DJ: Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002; 16: 361-78.
11. van der MEER A, WULFFRAAT NM, PRAKKEN BJ, GIJSBERS B, RADEMAKER CM, SINNEMA G: Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 2007; 25: 480-5.
12. ORTIZ-ALVAREZ O, MORISHITA K, AVERY G et al.: Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2501-6.
13. DHIR V, AGGARWAL A: Methotrexate-related minor adverse effects in rheumatoid arthritis:more than a nuisance. J Clin Rheumatol 2012; 18: 44-6.
14. VEYRAT-FOLLET C, FARINOTTI R, PALMER JL: Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Drugs 1997; 53: 206-34.
15. BULATOVIC M, HEIJSTEK MW, VERKAAIK M et al.: High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 2011; 63: 2007-13.
16. BRUNNER HI, JOHNSON AL, BARRON AC et al.: Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis:validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol 2005; 11: 194-204.
17. HORNEFF G: Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 2013; 13: 361-76.
18. RAMANAN AV, WHITWORTH P, BAILDAM EM: Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 197-200.
19. HAMILTON RA, KREMER JM: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86-90.
20. TERESI ME, CROM WR, CHOI KE, MIRRO J, EVANS WE: Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987; 110: 788-92.
21. TUKOVA J, CHLADEK J, NEMCOVA D, CHLADKOVA J, DOLEZALOVA P: Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2009; 27: 1047-53.
22. KLEIN A, KAUL I, FOELDVARI I, GANSER G, URBAN A, HORNEFF G: Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis:an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken) 2012; 64: 1349-56.
23. PETTY RE, SOUTHWOOD TR, MANNERS P et al.: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
24. CONSOLARO A, RUPERTO N, BAZSO A et al.: Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66.
25. HORNBY PJ: Central neurocircuitry associated with emesis. Am J Med 2001; 111 (Suppl. 8A): 106S-12S.
26. RAVELLI A, MIGLIAVACCA D, VIOLA S, RUPERTO N, PISTORIO A, MARTINI A: Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999; 17: 625-7.
27. BECKER ML, GAEDIGK R, Van HAANDEL L et al.: The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011; 63: 276-85.
28. BULATOVIC CALASAN M, Den BOER E, de ROTTE MC et al.: Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis 2013.
29. de ROTTE MC, den BE, de JONG PH et al.:Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 2013.
30. AMARILYO G, RULLO OJ, McCURDY DK, WOO JM, FURST DE: Folate usage in MTXtreated juvenile idiopathic arthritis (JIA) patients is inconsistent and highly variable. Rheumatol Int 2013; 33: 2437-40.
31. PATIL P, PARKER RA, RAWCLIFFE C et al.: Methotrexate-induced nausea and vomiting in adolescent and young adult patients. Clin Rheumatol 2014; 33: 403-7.
32. BULATOVIC CALASAN M, van den BOSCH OF, CREEMERS MC et al.: Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 2013; 15: R217.